Intra-dialytic hypotension (IDH) is defined as a fall in systolic blood pressure by ≥20 mmHg or in mean arterial pressure (MAP) by 10 mmHg correlated with symptoms, which include nausea, abdominal discomfort, yawning, sighing, vomiting, muscle cramps, restlessness, dizziness or fainting, and anxiety. It is the most common complications associated with hemodialysis treatment, which impairs the well-being of patient. Apart from that, it can aggravate cardiac arrhythmias and influence the coronary or result in cerebral ischemic diseases. In addition, the clinical IDH obstructs with an accurate dose delivery of dialysis therapeutics, as hypotension episodes lead to the compartment effect and cause suboptimal Kt/vUrea. Amongst the global population suffering from kidney failure, 76% of dialysis patients are reported to consume anti- hypertensive medications. Intra-dialytic hypotension is observed in 15% of the hemodialysis patients.
Since past few years, IDH market has gained traction, witnessed vertical growth and this trend is expected to continue during the forecast period. The main reason for this growth is the increasing number of patients suffering from kidney disorders and undergoing dialysis treatment globally. Other drivers for this market are the technological advancements in the medical field. Recent technological trends such as hemodialysis testing devices along with blood pressure monitors are beneficial for patients. Online hematocrit monitoring devices aid in the calculation of plasma volume changes, ultrafiltration, and plasma refill rates (such as UFR, PRR). The mismatch in the plasma refill rates help to interpret the physiology of intra-dialytic hypotension episodes. Technological reach of advanced instruments and recent trends of IDH devices in developing nations would be a key opportunity for this market. However, low purchasing power and unavailability of hospitals equipped with necessary facilities for patients are the major restraints in this market.
The IDH market is segmented based on location of testing, type of testing devices, and geography. Based on the type of testing devices, the market is further segmented into hospital testing devices and point-of-care (PoC) devices. Point-of-care (PoC) devices are beneficial for patients as they monitor inter- as well as intra-dialytic hypotension episodes. Currently, hospitals perform a majority of tests and would continue to hold a larger market share. Based on the location of testing, the market is segmented into hospital, clinic, and home testing. Geographically, the global IDH market is segmented into North America, Europe, Asia-Pacific, and LAMEA. North America and Europe dominate the global market owing to extensive R&D efforts and the implementation of recent technological advancements in the market.
Product launch is the key strategy followed by a majority of the key players in the market. For instance, Omron Healthcare Inc., have launched the 3 Series and 7 Series Wrist Blood Pressure Monitor for advanced measurements of blood pressure. Aetna Inc., lighTouch Medical Inc., Cnsystems Medizintechnik AG, Memscap SA, Fresenius Medical Care, SunTech Medical, W. A. Baum Co. Inc., Siemens Corporate Research Inc., Omron healthcare Inc., Corporation, are some of the key leaders in the global IDH market.
KEY MARKET SEGMENTS
The market is segmented based on the type of testing devices, location of testing, and by the geography.
BY TYPE OF TESTING DEVICES
BY LOCATION OF TESTING